Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish...
Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish...
Aptose在2024年ASH大會上展示了支持Tuspetinib與Venetoclax和Azacitidine聯合治療新診斷的急性髓性白血病（AML）的數據，強調了在FLT3野生型和先前VEN失敗人群中的廣泛療效，良好的安全性，以及建立潛力...
Aptose Presents Data At ASH 2024 Supporting Tuspetinib Triple Therapy With Venetoclax And Azacitidine In Newly Diagnosed AML, Highlighting Broad Efficacy In FLT3 Wildtype And Prior-VEN Failure Populations, Favorable Safety, And Potential To Establish Mutation-Agnostic Standard Of Care For Chemotherapy-Ineligible Patients
Aptose 在 2024 年 ASH 年會展示數據，支持與 Venetoclax 和 Azacitidine 結合的 Tuspetinib 三聯療法用於新診斷的急性髓系白血病，突出了在 FLT3 常規型和先前耐 Venetoclax 失敗人群中的廣泛療效，良好的安全性，並有潛力爲不適合化療的患者建立無突變標準治療。
資訊熱榜
更新時間